mySugr + Roche = a powerful combination for diabetes management

Congratulations to all at mySugr and their partners at Roche for sealing an incredible deal! mySugr will remain an open platform while integrating further with Roche products, a win-win for all involved - especially users.

I was pleased to help with PR for the US launch of mySugr a few years ago. I've personally recommended it to dozens of people over the years. Its rich features, intuitive interface and ability to pick up data passively from certain devices go a long way to reducing the tedium of logging. In contrast, Roche's diabetes management software offerings have always seemed complex to me, both in terms of their technical operation and how they display data.

Here's hoping the tie-up with mySugr will mean the next generation of Roche data management offers both an amazing user experience and awesome data visualisation. 

Gore - into the elements with ViaCyte

The past few weeks were uncharacteristically quiet in terms of diabetes deals. Then W. L. Gore & Associates, the manufacturer of Gore-Tex waterproof fabrics, announced a partnership with ViaCyte, the company developing VC-01, an implantable 'shark cage' containing insulin-producing cells.

This is a fascinating development and it raises a few questions. First, does Gore know what they are in for with a medical device? Yes. While their profile may be higher in weatherproof gear, they have an impressive portfolio of implantable medical devices under the auspices of Gore Medical Products in addition to the capabilities of Gore PharmBIO, the business unit partnering with ViaCyte. Second, does ViaCyte need this deal? Yes. Fibrosis has been noted with implantable beta cell projects over the years and ViaCyte has had their own issues along these lines. Third, will it work? We can hope so. For all the promise of VC-01, extending the life of the the implant insofar as possible must be a priority for the device to be commercially successful.

Versus biosimilars and Voluntis, how far can V-Go get?

Monday's news of a US $60 million IPO for Valeritas, the company behind the V-Go daily disposable insulin pump product for type 2 diabetes, raises a few big questions for potential investors and prescribers to ponder:

  • As BI/Lilly's Abasalgar (Basaglar in the US) gains traction, to what extent will healthcare payers promote the use of biosimilar glargine as the first line of insulin therapy for all people with type 2 diabetes?
  • Sanofi and Voluntis last week announced a non-exclusive tech partnership to improve Lantus (glargine 100 U) titration, towards optimising injected basal insulin therapy. Interestingly, there's no mention of Sanofi's newer long-acting insulin Toujeo (glargine 300 U) in the coverage. Is this a sign of Sanofi doubling down to maintain insulin market share with Lantus?
  • We've been hearing about the V-Go for so long and CeQur has hit a rough patch on the road towards commercial launch of its durable+consumables Paq product for type 2 diabetes. Will the insulin treatment pathway for type 2s evolve from 1 x basal (+/- orals) -->MDI to include V-Go or Paq quickly enough for both companies to stay afloat?